DC Chemicals

DC60510 · Updated 28 October 2026

Iso-A11B5C1

Literature evidence · DC60510

Formulation & Performance

The optimized muscle-delivery formulation uses a C14 PEG phospholipid. Its results should not be transferred to a formulation in which that component is replaced by DMG-PEG2000.

The results below describe the cited research formulations. Product specifications and commercial pack options are shown in the Specifications and ordering sections.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
Iso-A11B5C1DC60510662.1600.397260
DOPEDC33634744.03100.074403
CholesterolDCD-041386.65290.112128
C14-PEG2000 (14:0 PEG2000 PE)Not uniquely mappedNot established1Not calculable from disclosed data

Optimized molar composition = 60:10:29:1; ionizable lipid:mRNA = 10:1 by weight. The SI identifies 14:0 PEG2000 PE as the PEG lipid. Its exact commercial product mapping and molecular weight are not assigned here. This is not DMG-PEG2000; total mass fractions remain uncalculated until its molecular weight is specified. N/P was not reported.

Component mass calculator

Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
Iso-A11B5C1——
DOPE——
Cholesterol——
C14-PEG2000 (14:0 PEG2000 PE)——

Formulation characteristics

ParameterEvidenceSource / boundary
Apparent pKaApproximately 7.2Main Fig. 3B; formulation ionization measurement.
Size / PDIParticle-size and dispersity measurements are plottedSI Fig. S4, p. 9. No exact mean is transcribed from the graph.
Encapsulation>80% was an optimization selection criterionThe criterion is not a final-batch numerical encapsulation result. SI Table S2 compares screening formulations.
Helper-lipid identityDOPE; C14-PEG2000 phospholipidMethods and SI. Unverified substitutions are not used in the component calculator.

Cell-line selectivity

Cell modelComparison with SM-102 LNPsInterpretation
HeLa42-fold higher reporter expressionMain Fig. 3A; cell-line-specific comparison.
HepG228-fold lower reporter expressionMain Fig. 3A; supports reduced expression in this hepatic cell model.
Splenocytes24-fold lower reporter expressionMain Fig. 3A; does not imply absence of particle exposure.

Intramuscular delivery and off-target expression

StudyConditionsReported outcome
Luciferase mRNAC57BL/6J mice; 0.3 mg/kg IM; 6 h; n = 3Local expression comparable to SM-102; no significant difference reported. Liver/spleen off-target expression was not detected under the assay conditions (Fig. 2).
Cre mRNA reportermTmG mice; 0.5 mg/kg IM; 36 h; n = 3Muscle reporter activation comparable to SM-102; Iso-A11B5C1 activation not detected in liver/spleen (Fig. 4).
SM-102 Cre comparatorSame reporter study83.83% liver and 72.67% spleen reporter activation reported for the comparator. These are reporter readouts, not injected-dose recovery.

Five tissue sections were averaged per mouse in the Cre analysis. Cre-dependent recombination is distinct from CRISPR editing. Undetected expression does not demonstrate zero tissue exposure.

Tumour response and acute tolerability

EndpointReported evidenceLimit
Trp2 mRNA / B16F10 modelDoses administered on days 7 and 12; tumour control exceeded MC3 but was less effective than SM-102Main Fig. 5; do not describe Iso-A11B5C1 as superior across all efficacy endpoints.
Acute cytokinesBALB/c mice, 0.5 mg/kg IM; six cytokines at 4 h showed no discernible difference from PBSSI Fig. S8; one acute time point does not establish systemic or repeat-dose safety.

Original study figures

Original Figures 2–5 and Supporting Information — Original source figures.

References and source locations

  1. Chen J, Xu Y, Zhou M, et al. Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects. PNAS 120, e2309472120 (2023). DOI: 10.1073/pnas.2309472120.
  2. Full text and Supporting Information, Table S2 and Figures S4/S8.